NASDAQ: SRTAStrata Critical Medical Inc Stock
$5.20+0.30 (+6.12%)
Updated Sep 17, 2025
SRTA Price
$5.20
Fair Value Price
N/A
Market Cap
$424.82M
52 Week Low
$2.35
52 Week High
$5.60
P/E
-21.67x
P/B
1.9x
P/S
1.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$254.34M
Earnings
-$18.98M
Gross Margin
24.4%
Operating Margin
-7.55%
Profit Margin
-7.5%
Debt to Equity
0.16
Operating Cash Flow
$1M
Beta
1.42
Next Earnings
Nov 10, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SRTA Overview
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SRTA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Airport
Industry Rating
B
SRTA
Ranked#5 of 10
Ranked#5 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.33 | A | |
| $106.77 | B | |
| $18.80 | B |
Be the first to know about important SRTA news, forecast changes, insider trades & much more!
SRTA News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SRTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SRTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SRTA is good value based on its book value relative to its share price (1.9x), compared to the US Airports & Air Services industry average (6.45x)
P/B vs Industry Valuation
SRTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SRTA due diligence checks available for Premium users.
Valuation
SRTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-21.67x
Industry
10.57x
Market
37.36x
SRTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.9x
Industry
6.45x
SRTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SRTA's financial health
Profit margin
Revenue
$70.8M
Net Income
-$3.7M
Profit Margin
-5.3%
SRTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SRTA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$257.9M
Liabilities
$34.8M
Debt to equity
0.16
SRTA's short-term assets ($156.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SRTA's short-term assets ($156.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SRTA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SRTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$28.7M
Financing
-$1.1M
SRTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SRTA vs Airport Stocks
Strata Critical Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.